1 Ocak 2017 Dergi makalesi Açık Erişim

Erturk, Zeliha; Buber, Esra; Ozen, Haluk; Celikbicak, Omur; Salih, Bekir; Acan, N. Leyla

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 47033, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Med, Dept Med Biochem, Ankara, Turkey", 
      "name": "Erturk, Zeliha"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Med, Dept Med Biochem, Ankara, Turkey", 
      "name": "Buber, Esra"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Med, Dept Urol, Ankara, Turkey", 
      "name": "Ozen, Haluk"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Sci, Dept Chem, Ankara, Turkey", 
      "name": "Celikbicak, Omur"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Sci, Dept Chem, Ankara, Turkey", 
      "name": "Salih, Bekir"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Med, Dept Med Biochem, Ankara, Turkey", 
      "name": "Acan, N. Leyla"
    }
  ], 
  "datePublished": "2017-01-01", 
  "description": "Objective: Immunotherapy with intravesical Bacillus Calmette-Guerin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We aimed to develop less toxic and more powerful therapeutic agents for the treatment of bladder cancer than live strain.", 
  "headline": "Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer", 
  "identifier": 47033, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer", 
  "url": "https://aperta.ulakbim.gov.tr/record/47033"
}